nyuuzyou/wikis huggingface dataset:
Radotinib (Supect)

Not currently approved in the United States.
==Mechanism of action==
From the NCI Drug Dictionary: a second-generation tyrosine kinase inhibitor of Bcr-Abl fusion protein and the platelet-derived growth factor receptor (PDGFR), with potential antineoplastic activity. Upon administration, radotinib specifically inhibits the Bcr-Abl fusion protein, an abnormal enzyme expressed in Philadelphia chromosome-positive chronic myeloid leukemia (CML) cells. In addition, this agent also inhibits PDGFR thereby blocking PDGFR-mediated signal transduction pathways.
==Diseases for which it is used==
*Chronic myeloid leukemia
==Also known as==
*Code name: IY5511HCl
*Brand name: Supect
Category:Drugs
Category:Oral medications
Category:Bcr-Abl inhibitors
Category:PDGFR inhibitors
Category:Chronic myeloid leukemia medications
Category:KFDA approved in 2012
Raloxifene (Evista)

==General information==
Class/mechanism: SERM (selective estrogen receptor modulator), with estrogen agonist/antagonist properties depending on tissue type. Raloxifene has estrogen antagonist properties in uterine and breast tissues. However, it has estrogen agonist properties in bone, helping to decrease bone resorption.Raloxifene (Evista) package insertRaloxifene (Evista) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Patient drug information==
*Raloxifene (Evista) patient drug information (Chemocare)Raloxifene (Evista) patient drug information (Chemocare)
*Raloxifene (Evista) patient drug information (UpToDate)Raloxifene (Evista) patient drug information (UpToDate)
==History of changes in EMA indication==
*1998-08-05: EURD
==Also known as==
*Brand names: Evista, Ralista, Razylan
==References==
Category:Drugs
Category:Oral medications
Category:Selective estrogen receptor modulators
Category:FDA approved in 1997
Category:EMA approved in 1998
Raltitrexed (Tomudex)

==General information==
Class/mechanism: Antimetabolite, inhibitor of thymidylate synthase. Raltitrexed is a quinazoline folate analog which inhibits thymidylate synthase (TS). TSis an enzyme involved in the synthesis of thymidine triphosphate (TTP), a nucleotide required exclusively for DNA synthesis. Inhibiting TS causes DNA damage and cell death.Raltitrexed (Tomudex) package insert Raltitrexed (Tomudex) package insert (locally hosted backup)
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
No information available.
==Diseases for which it is established (work in progress)==
*Malignant pleural mesothelioma
==Diseases for which it is used==
*Colorectal cancer
==History of changes in EMA indication==
*1995-11-08: EURD
==Also known as==
*Code names: TDX, ZD-1694
*Generic name: raltitrexed disodium
*Brand name: Tomudex
==References==
Category:Drugs
Category:Intravenous medications
Category:Antimetabolites
Category:Antifolates
Category:Colorectal cancer medications
Category:Malignant pleural mesothelioma medications
Category:EMA approved in 1995
Category:Health Canada approved drugs
Ramosetron (Iribo)

==Mechanism of action==
Serotonin 5-HT3 receptor antagonist with antiemetic properties. No known antineoplastic properties. Not FDA-approved; available in Japan and Southeast Asia.
==Also known as==
*Brand names: IBset, Iribo, Irribow, Nasea, Nozia
 
Category:Drugs
Category:Oral medications
Category:Intravenous medications
Category:Emesis prevention
Category:Serotonin 5-HT3 antagonists
Category:PMDA approved in 2015
Ranimustine (Cymerin)

==Mechanism of action==
From the NCI Drug Dictionary: A chloroethylnitrosourea derivative that inhibits proliferation and growth of tumor cells by alkylation and cross-linkage of DNA strands of tumor cells.
==Diseases for which it used==
*Adult T-cell leukemia-lymphoma
==Also known as==
*Generic name: MCNU, ranomustine
*Brand names: Cymer, Cymerin
Category:Drugs
Category:Intravenous medications
Category:Nitrosoureas
Category:Adult T-cell leukemia-lymphoma medications
Category:PMDA approved drugs
Rasburicase (Elitek)

==General information==
Class/mechanism: Recombinant urate-oxidase. Rasburicase catalyzes the enzymatic oxidation of poorly soluble uric acid into allantoin, an inactive and more soluble metabolite.Rasburicase (Elitek) package insert Rasburicase (Elitek) package insert (locally hosted backup)Elitek manufacturer's website
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information. 
==Patient drug information==
*Brief patient counseling information can be found in the Rasburicase (Elitek) package insert 
==History of changes in FDA indication==
*2002-07-12: Approved for initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid.
==History of changes in EMA indication==
*2001-02-23: Initial authorization as Fasturtec
==History of changes in PMDA indication==
*2009-10-16: Initial approval for the treatment of hyperuricemia in patients receiving cancer chemotherapy.
==Also known as==
*Brand names: Elitek, Fasturtec, Rasbelon, Rasburnat, Rasby
==References==
Category:Drugs
Category:Intravenous medications
Category:Recombinant medications
Category:Urate oxidase
Category:EMA approved in 2001
Category:FDA approved in 2002
Category:PMDA approved in 2009
Category:WHO Essential Cancer Medicine
Ravulizumab (Ultomiris)

==General information==
Class/mechanism from the NCI Drug Dictionary: A longer-acting antibody directed against terminal complement protein C5, with potential anti-inflammatory activity. Upon administration, ravulizumab-cwvz binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and preventing the complement-mediated destruction of red blood cells (RBCs) as seen in paroxysmal nocturnal hemoglobinuria (PNH). Compared to other anti-C5 antibodies, ALXN1210 is longer-acting and allows for monthly dosing.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Toxicity management==
*Link to REMS program
==Diseases for which it is used==
*Atypical hemolytic uremic syndrome
*Paroxysmal nocturnal hemoglobinuria
==History of changes in FDA indication==
* 2018-12-21: Initial approval for adult patients with paroxysmal nocturnal hemoglobinuria (PNH). (Based on CHAMPION 301 & CHAMPION 302)
==History of changes in EMA indication==
*2019-07-02: Initial authorization
==History of changes in PDMA indication==
*2020-09-25: New indication and a new dosage for the treatment of atypical hemolytic uremic syndrome (aHUS).
==Also known as==
*Code name: ALXN-1210
*Generic name: ravulizumab-cwvz 
*Brand name: Ultomiris
==References==
Category:Drugs
Category:Intravenous medications
Category:Anti-C5 antibodies
Category:Hematology medications
Category:Atypical hemolytic uremic syndrome medications
Category:Paroxysmal nocturnal hemoglobinuria medications
Category:FDA approved in 2018
Category:EMA approved in 2019
Category:REMS program
Realgar-Indigo naturalis formulation

==Mechanism of action==
From Wikipedia: The basic action of this medication is similar to arsenic trioxide in that the arsenic component triggers degradation of the PML-RARα oncoprotein, by shifting the protein out of the nucleoplasm onto the nuclear matrix.
From the NCI Drug Dictionary: An orally bioavailable, traditional Chinese medicine (TCM)-based formulation composed of Realgar-Indigo naturalis formula (RIF) with potential antineoplastic activity. The main constituents in RIF are realgar, Indigo naturalis, and Salvia miltiorrhiza, with tetraarsenic tetrasulfide (As4S4), indirubin and tanshinone IIA as the main active ingredients, respectively, which appear to exert synergistic effects on cancer cells. Tetraarsenic tetrasulfide specifically induces the ubiquitination and degradation of the oncoprotein promyelocytic leukemia retinoic acid receptor alpha (PML-RARalpha). In addition, the active ingredients in the Realgar-Indigo naturalis formulation enhance the expression of myeloid differentiation genes, and induce G(1)/G(0) cell cycle arrest. 
==Also known as==
*Generic name: Compound Huangdai
Category:Drugs
Category:Oral medications
Category:Arsenic compound
Category:Acute promyelocytic leukemia medications
Category:NMPA approved in 2009
Category:WHO Essential Medicines
Category:Stub
Rebimastat (BMS-275291)

==Mechanism of action==
From the NCI Drug Dictionary: A substance that is being studied in the treatment of cancer. It belongs to the family of drugs called matrix metalloproteinase inhibitors (MMPIs).
==Also known as==
*Code names: BMS-275291, D2163
Category:Drugs
Category:Oral medications
Category:Matrix metalloproteinase inhibitors
Category:Investigational drugs
Category:Stub
Refametinib (BAY-869766)

==Mechanism of action==
From the NCI Drug Dictionary: An orally bioavailable selective MEK inhibitor with potential antineoplastic activity. Refametinib specifically inhibits mitogen-activated protein kinase kinase 1 (MAP2K1 or MAPK/ERK kinase 1), resulting in inhibition of growth factor-mediated cell signaling and tumor cell proliferation.
==Preliminary data==
===Hepatocellular carcinoma===
# Lim HY, Merle P, Weiss KH, Yau T, Ross P, Mazzaferro V, Blanc JF, Ma YT, Yen CJ, Kocsis J, Choo SP, Sukeepaisarnjaroen W, Gérolami R, Dufour JF, Gane EJ, Ryoo BY, Peck-Radosavljevic M, Dao T, Yeo W, Lamlertthon W, Thongsawat S, Teufel M, Roth K, Reis D, Childs BH, Krissel H, Llovet JM. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma. Clin Cancer Res. 2018 Oct 1;24(19):4650-4661. Epub 2018 Jun 27. link to original article PubMed
==Also known as==
*Code name: BAY-869766
Category:Drugs
Category:Oral medications
Category:MAP2K1 inhibitors
Category:Investigational drugs
Regimen classes

The purpose of this page is to define regimen classes that will be used in the HemOnc ontology; it is not for other purposes at this time.
=Generic classes=
==Allogeneic HSCT==
==Chemoradiotherapy-based regimen==
==Chemotherapy-based regimen==
===Biochemotherapy===
===High-dose chemotherapy with auto HSCT===
===Intensive chemotherapy===
==Endocrine therapy-based regimen==
==Radiotherapy-based regimen==
==Single-agent regimen==
===Single-agent cytotoxic chemotherapy===
===Single-agent endocrine therapy===
===Single-agent immunotherapy===
===Single-agent targeted therapy===
==Multi-agent regimen==
===Multi-agent cytotoxic chemotherapy===
=Named classes=
All classes in this category have at least one named agent or class of agents other than the most generic classes of chemotherapy, immunotherapy, etc.
==Alkylator-based regimen==
==Anthracycline-based regimen==
===Doxorubicin-based regimen===
==Anti-CD20-based regimen==
===Rituximab-containing regimen===
==Anti-HER2-based regimen==
===Trastuzumab-based regimen===
==Anti-VEGF biologic therapy==
===Bevacizumab-containing regimen===
==Dacarbazine-based regimen==
==Endocrine-based regimen==
===Androgen receptor-directed therapy===
===Antiestrogen therapy===
==Fludarabine-based regimen==
==Fluoropyrimidine-based regimen==
===Fluoropyrimidine-based chemoradiotherapy===
====5-FU-based chemoradiotherapy====
===5-FU-based regimen===
==Fluoropyrimidine- and platinum-based regimen==
==Irinotecan-based regimen==
==Pemetrexed-containing regimen==
==Platinum-based regimen==
===Cisplatin-based regimen===
===Oxaliplatin-based regimen===
===Platinum-based chemoradiation===
===Platinum-taxane-based regimen===
===Platinum doublet===
==Taxane-based regimen==
===Docetaxel-containing regimen===
===Paclitaxel-containing regimen===
==Temozolomide-based regimen==
==Tyrosine kinase inhibitor therapy==
===BRAF TKI therapy===
===EGFR TKI therapy===
===VEGFR inhibitor therapy===
=Modeled classes=
This unusual category includes regimens that are "like" another regimen, without exactly specifying how they are like.
====CHOP-like therapy====
====R-CHOP-like therapy====
Category:Ontology pages
Relugolix (Orgovyx)

==General information==
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with relugolix, in contrast to GnRH agonists.Relugolix manufacturer's websiteRelugolix (Orgovyx) package insertRelugolix (Orgovyx) package insert (locally hosted backup)
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is used==
*Prostate cancer
==Patient drug information==
*Relugolix (Orgovyx) package insert
*Relugolix (Orgovyx) patient drug information (UpToDate)Relugolix (Orgovyx) patient drug information (UpToDate)
==History of changes in FDA indication==
*2020-12-18: Approved for adult patients with advanced prostate cancer. (Based on HERO)
==History of changes in EMA indication==
*2022-04-29: Initial authorization as Orgovyx. Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer. (Based on HERO)
==History of changes in PMDA indication==
*2019-01-08: Initial approval for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids.
==Also known as==
*Code name: TAK-385
*Brand names: Orgovyx, Relumina
==References==
Category:Drugs
Category:Oral medications
Category:GnRH antagonists
Category:Prostate cancer medications
Category:FDA approved in 2020
Category:EMA approved in 2022
Category:PMDA approved in 2019
Remestemcel-L (Ryoncil)

==Mechanism of action==
Allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy
==History of changes in FDA indication==
*2024-12-18: Initial approval for steroid-refractory acute graft versus host disease (SR-aGVHD) in pediatric patients 2 months of age and older. (Based on MSB-GVHD001)
==Also known as==
*Generic name: remestemcel-L-rknd
*Brand name: Ryoncil
Category:Mesenchymal stromal cells
Category:Intravenous medications
Category:Graft versus host disease medications
Category:FDA approved in 2024
Renal cell carcinoma, VHL-associated

Back to Top
Note: these are regimens tested in populations with a diagnosis of Von Hippel Lindau (VHL) Disease-associated renal cell carcinoma, please see the main RCC page for other regimens.
Last updated on 2024-07-23:1 regimens on this page
1 variants on this page
=Guidelines=
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any guideline published 5+ years ago to be for historical purposes, only.
==NCCN==
*NCCN does not currently have guidelines at this granular level; please see NCCN Guidelines - Kidney Cancer.
=All lines of therapy=
==Belzutifan monotherapy==
===Regimen===
Study 	Dates of enrollment 	Evidence
Jonasch et al. 2021 (MK-6482-004)	2018-05-31 to 2019-03-29	Phase 2 (RT)
====Targeted therapy====
*Belzutifan (Welireg) 120 mg PO once per day
Continued indefinitely
===References===
# MK-6482-004: Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R; MK-6482-004 Investigators. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 Nov 25;385(22):2036-2046. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT03401788
Category:Renal cell carcinoma regimens
Category:Biomarker-specific pages
Category:Renal cell carcinomas
Repotrectinib (Augtyro)

==General information==
Class/mechanism from the NCI Drug Dictionary: An orally available inhibitor of multiple kinases, including the receptor tyrosine kinase anaplastic lymphoma kinase (ALK), c-ros oncogene 1 (ROS1), the neurotrophic tyrosine receptor kinase (NTRK) types 1, 2 and 3, the proto-oncogene SRC, and focal adhesion kinase (FAK), with potential antineoplastic activity. Upon oral administration, repotrectinib binds to and inhibits wild-type, point mutants and fusion proteins of ALK, ROS1, NTRK1-3, SRC, FAK and, to a lesser extent, other kinases. Inhibition of these kinases leads to the disruption of downstream signaling pathways and the inhibition of cell growth of tumors in which these kinases are overexpressed, rearranged or mutated.
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Diseases for which it is established==
*ROS1+ NSCLC
==History of changes in FDA indication==
*2023-11-15: Approved for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). (Based on TRIDENT-1)
*2024-06-13: Granted accelerated approval for adult and pediatric patients 12 years and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity, and that have progressed following treatment or have no satisfactory alternative therapy. (Based on TRIDENT-1)
==Patient Drug Information==
==Also known as==
*Code name: TPX-0005
*Brand name: Augtyro
==References==
Category:Drugs
Category:Oral medications
Category:ALK inhibitors
Category:ROS1 inhibitors
Category:SRC inhibitors
Category:FAK inhibitors
Category:TRK inhibitors
Category:Mutation-specific medications
Category:Non-small cell lung cancer medications
Category:FDA approved in 2023
Retaspimycin (IPI-504)

==General information==
Class/mechanism: Hsp90 (heat shock protein 90) inhibitor. Hsp90 is a molecular chaperone that stabilizes various cellular proteins, such as growth factor receptors and molecules involved in signal transduction. Hsp90 is overexpressed in cancer cells and may help to stabilize less stable proteins produced by DNA mutations. By inhibiting Hsp90, retaspimycin may accelerate degradation of growth factors and increase the sensitivity of cancer cells to environmental stress, leading to apoptosis of tumor cells.Retaspimycin (IPI-504) manufacturer's websiteGIST Support International (GSI) page about Retaspimycin (IPI-504)
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Patient drug information==
No information available.
==Also known as==
*Code name: IPI-504
==References==
Category:Drugs
Category:Intravenous medications
Category:Hsp90 inhibitors
Category:Investigational drugs
Retifanlimab (Zynyz)

==Mechanism of action==
From NCI Drug Dictionary: A proprietary humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, retifanlimab binds to and inhibits PD-1 and its downstream signaling pathways. This may restore immune function through the activation of T cells and cell-mediated immune responses against tumor cells.
==Diseases for which it is used==
*Merkel cell carcinoma
==History of changes in FDA indication==
*2023-03-22: Granted accelerated approval for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC). (Based on POD1UM-201)
==Also known as==
*Code name: INCMGA 0012, MGA 012
*Generic name: retifanlimab-dlwr
*Brand name: Zynyz
Category:Drugs
Category:Intravenous medications
Category:Anti-PD-1 antibodies
Category:Merkel cell carcinoma medications
Category:FDA approved in 2023